Cabaten/Getne-T1914: Cabozantinib Plus Atezolizumab In Adrenocortical Carcinoma

CABATEN/GETNE-T1914: cabozantinib plus atezolizumab in adrenocortical carcinoma

Cabozantinib demonstrates disease control in advanced adrenocortical carcinoma

COSMIC-021: Cabozantinib + atezolizumab gives clinical activity in inoperable metastatic UC

ASCO 2022: Efficacy of Cabozantinib + Atezolizumab to Treat Urothelial Carcinoma

Cabozantinib Plus Atezolizumab for Non-Clear Cell Renal Cell Carcinoma

CONTACT-303: primary PFS analysis of atezolizumab and cabozantinib in ccRCC

Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPC

Cabozantinib in combination with atezolizumab in patients with mCRPC

Cab + atezo: a new treatment for naïve advanced ccRCC

PAPMET2: cabozantinib with or without atezolizumab in PRCC

Cabozantinib in patients with HCC refractory to checkpoint inhibitors

Daniel Petrylak, MD, on investigating atezolizumab and cabozantinib relating to prostate cancer

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Dr. Apolo on Side Effects of Cabozantinib Plus Immunotherapy Agents in Bladder Cancer

Cabozantinib With Atezolizumab for mCRPC

Managing adrenocortical carcinoma with immunotherapies

Dr. Apolo on the Combination of Cabozantinib Plus Nivolumab in Urothelial Carcinoma

Final analysis of the ATLANTIS cabozantinib comparison

European Association of Urology

Telaglenastat Plus Cabozantinib for Advanced Renal Cell Carcinoma

Neoadjuvant atezolizumab for advanced cutaneous squamous cell carcinoma